GZ BYS PHARMACE -H-
GZ BYS PHARMACE -H- operates in Diversified Metals & Mining.
GZ BYS PHARMACE -H- (GU5) - Total Assets
Latest total assets as of September 2024: €79.26 Billion EUR
Based on the latest financial reports, GZ BYS PHARMACE -H- (GU5) holds total assets worth €79.26 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GZ BYS PHARMACE -H- - Total Assets Trend (2016–2023)
This chart illustrates how GZ BYS PHARMACE -H-’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GZ BYS PHARMACE -H- - Asset Composition Analysis
Current Asset Composition (December 2023)
GZ BYS PHARMACE -H-'s total assets of €79.26 Billion consist of 71.2% current assets and 28.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.1% |
| Accounts Receivable | €15.11 Billion | 19.2% |
| Inventory | €11.51 Billion | 14.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.20 Billion | 4.1% |
| Goodwill | €829.47 Million | 1.1% |
Asset Composition Trend (2016–2023)
This chart illustrates how GZ BYS PHARMACE -H-'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GZ BYS PHARMACE -H-'s current assets represent 71.2% of total assets in 2023, a decrease from 75.4% in 2016.
- Cash Position: Cash and equivalents constituted 27.1% of total assets in 2023, down from 50.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 19.2% of total assets.
GZ BYS PHARMACE -H- Competitors by Total Assets
Key competitors of GZ BYS PHARMACE -H- based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
GZ BYS PHARMACE -H- - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - GZ BYS PHARMACE -H- generates 0.96x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, GZ BYS PHARMACE -H- generates $5.16 in net profit.
GZ BYS PHARMACE -H- - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.46 | 1.62 | 1.57 |
| Quick Ratio | 1.15 | 1.32 | 1.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €16.79 Billion | € 20.24 Billion | € 16.61 Billion |
GZ BYS PHARMACE -H- - Advanced Valuation Insights
This section examines the relationship between GZ BYS PHARMACE -H-'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.3% |
| Total Assets | €78.59 Billion |
| Market Capitalization | $20.36K USD |
Valuation Analysis
Below Book Valuation: The market values GZ BYS PHARMACE -H-'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: GZ BYS PHARMACE -H-'s assets grew by 5.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GZ BYS PHARMACE -H- (2016–2023)
The table below shows the annual total assets of GZ BYS PHARMACE -H- from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €78.59 Billion | +5.25% |
| 2022-12-31 | €74.67 Billion | +12.93% |
| 2021-12-31 | €66.12 Billion | +10.64% |
| 2020-12-31 | €59.76 Billion | +5.04% |
| 2019-12-31 | €56.89 Billion | +10.51% |
| 2018-12-31 | €51.48 Billion | +81.82% |
| 2017-12-31 | €28.31 Billion | +9.34% |
| 2016-12-31 | €25.90 Billion | -- |